Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 4/2013

01-08-2013

Defining vascular signatures of benign hepatic masses: role of MDCT with 3D rendering

Authors: Sameer Ahmed, Pamela T. Johnson, Elliot K. Fishman

Published in: Abdominal Radiology | Issue 4/2013

Login to get access

Abstract

Multidetector CT (MDCT) provides new opportunities for hepatic tumor characterization. By coupling high-resolution isotropic datasets with advanced post-processing tools, maps of tumor vascularity can be generated to elucidate characteristic findings. This two-part review describes a range of benign and malignant liver masses, with emphasis on IV contrast-enhanced MDCT features and vascular signatures that can be identified on 3D vascular mapping.
Literature
1.
Foley WD, Mallisee TA, Hohenwalter MD, et al. (2000) Multiphase hepatic CT with a multirow detector CT scanner. AJR Am J Roentgenol 175:679–685PubMedCrossRef
2.
Francis IR, Cohan RH, McNulty NJ, et al. (2003) Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR Am J Roentgenol 180:1217–1224PubMedCrossRef
3.
Johnson PT, Fishman EK (2006) IV contrast selection for MDCT: current thoughts and practice. AJR Am J Roentgenol 186:406–415PubMedCrossRef
4.
Yanaga Y, Awai K, Nakaura T, et al. (2008) Optimal contrast dose for depiction of hypervascular hepatocellular carcinoma at dynamic CT using 64-MDCT. AJR Am J Roentgenol 190:1003–1009PubMedCrossRef
5.
Bae KT (2010) Intravenous contrast medium administration and scan timing at CT: considerations and approaches. Radiology 256:32–61PubMedCrossRef
6.
Heiken JP, Brink JA, McClennan BL, et al. (1995) Dynamic incremental CT: effect of volume and concentration of contrast material and patient weight on hepatic enhancement. Radiology 195:353–357PubMed
7.
8.
Carrim ZI, Murchison JT (2003) The prevalence of simple renal and hepatic cysts detected by spiral computed tomography. Clin Radiol 58:626–629PubMedCrossRef
9.
Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287–1301PubMedCrossRef
10.
Inaba T, Nagashima I, Ogawa F, et al. (2003) Diffuse intrahepatic bile duct dilation caused by a very small hepatic cyst. J Hepatobiliary Pancreat Surg 10:106–108PubMed
11.
Mortele KJ, Segatto E, Ros PR (2004) The infected liver: radiologic–pathologic correlation. Radiographics 24:937–955PubMedCrossRef
12.
Halvorsen RA, Korobkin M, Foster WL, et al. (1984) The variable CT appearance of hepatic abscesses. AJR Am J Roentgenol 142:941–946PubMedCrossRef
13.
Zonios D, Soula M, Archimandritis AJ, et al. (2003) Cystlike hepatic metastases from gastrointestinal stromal tumors could be seen before any treatment. AJR Am J Roentgenol 181:282 (author reply 282)PubMedCrossRef
14.
15.
Karhunen PJ (1986) Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 39:183–188PubMedCrossRef
16.
Gandolfi L, Leo P, Solmi L, et al. (1991) Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut 32:677–680PubMedCrossRef
17.
Farges O, Daradkeh S, Bismuth H (1995) Cavernous hemangiomas of the liver: are there any indications for resection? World J Surg 19:19–24PubMedCrossRef
18.
Saegusa T, Ito K, Oba N, et al. (1995) Enlargement of multiple cavernous hemangioma of the liver in association with pregnancy. Intern Med 34:207–211PubMedCrossRef
19.
Biecker E, Fischer HP, Strunk H, et al. (2003) Benign hepatic tumours. Z Gastroenterol 41:191–200PubMedCrossRef
20.
Kamel IR, Liapi E, Fishman EK (2005) Liver and biliary system: evaluation by multidetector CT. Radiol Clin North Am 43:977–997, vii
21.
Oto A, Tamm EP, Szklaruk J (2005) Multidetector row CT of the liver. Radiol Clin North Am 43:827–848, vii
22.
Belli L, De Carlis L, Beati C, et al. (1992) Surgical treatment of symptomatic giant hemangiomas of the liver. Surg Gynecol Obstet 174:474–478PubMed
23.
Ungermann L, Elias P, Zizka J, et al. (2007) Focal nodular hyperplasia: spoke-wheel arterial pattern and other signs on dynamic contrast-enhanced ultrasonography. Eur J Radiol 63:290–294PubMedCrossRef
24.
Buetow PC, Pantongrag-Brown L, Buck JL, et al. (1996) Focal nodular hyperplasia of the liver: radiologic–pathologic correlation. Radiographics 16:369–388PubMed
25.
Wanless IR, Mawdsley C, Adams R (1985) On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology 5:1194–1200PubMedCrossRef
26.
Leconte I, Van Beers BE, Lacrosse M, et al. (2000) Focal nodular hyperplasia: natural course observed with CT and MRI. J Comput Assist Tomogr 24:61–66PubMedCrossRef
27.
Nguyen BN, Flejou JF, Terris B, et al. (1999) Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 23:1441–1454PubMedCrossRef
28.
Cherqui D, Rahmouni A, Charlotte F, et al. (1995) Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 22:1674–1681PubMedCrossRef
29.
Brancatelli G, Federle MP, Grazioli L, et al. (2001) Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology 219:61–68PubMed
30.
Johnson PT, Zaheer A, Anders R, et al. (2010) Dual-phase computed tomographic angiography of focal nodular hyperplasia: defining predictable postcontrast attenuation levels relative to aorta and inferior vena cava. J Comput Assist Tomogr 34:720–724PubMedCrossRef
31.
Welch TJ, Sheedy PF 2nd, Johnson CM, et al. (1985) Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology 156:593–595PubMed
32.
Yang CY, Ho MC, Jeng YM, et al. (2007) Management of hepatic angiomyolipoma. J Gastrointest Surg 11:452–457PubMedCrossRef
33.
Nonomura A, Mizukami Y, Kadoya M (1994) Angiomyolipoma of the liver: a collective review. J Gastroenterol 29:95–105PubMedCrossRef
34.
Buell JF, Tranchart H, Cannon R, et al. (2010) Management of benign hepatic tumors. Surg Clin North Am 90:719–735PubMedCrossRef
35.
Dalle I, Sciot R, de Vos R, et al. (2000) Malignant angiomyolipoma of the liver: a hitherto unreported variant. Histopathology 36:443–450PubMedCrossRef
36.
Croquet V, Pilette C, Aube C, et al. (2000) Late recurrence of a hepatic angiomyolipoma. Eur J Gastroenterol Hepatol 12:579–582PubMedCrossRef
37.
38.
39.
Soe KL, Soe M, Gluud C (1992) Liver pathology associated with the use of anabolic–androgenic steroids. Liver 12:73–79PubMed
40.
Reddy KR, Kligerman S, Levi J, et al. (2001) Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 67:173–178PubMed
41.
Rabe T, Feldmann K, Grunwald K, et al. (1994) Liver tumours in women on oral contraceptives. Lancet 344:1568–1569PubMedCrossRef
42.
Meissner K (1998) Hemorrhage caused by ruptured liver cell adenoma following long-term oral contraceptives: a case report. Hepatogastroenterology 45:224–225PubMed
43.
Dokmak S, Paradis V, Vilgrain V, et al. (2009) A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 137:1698–1705PubMedCrossRef
44.
Guttmacher AE, Marchuk DA, White RI Jr (1995) Hereditary hemorrhagic telangiectasia. N Engl J Med 333:918–924PubMedCrossRef
45.
Ianora AA, Memeo M, Sabba C, et al. (2004) Hereditary hemorrhagic telangiectasia: multi-detector row helical CT assessment of hepatic involvement. Radiology 230:250–259PubMedCrossRef
46.
Garcia-Tsao G, Korzenik JR, Young L, et al. (2000) Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 343:931–936PubMedCrossRef
47.
Buscarini E, Buscarini L, Danesino C, et al. (1997) Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: Doppler sonographic screening in a large family. J Hepatol 26:111–118PubMedCrossRef
48.
Memeo M, Stabile Ianora AA, Scardapane A, et al. (2004) Hepatic involvement in hereditary hemorrhagic telangiectasia: CT findings. Abdom Imaging 29:211–220PubMedCrossRef
49.
Buscarini E, Buscarini L, Civardi G, et al. (1994) Hepatic vascular malformations in hereditary hemorrhagic telangiectasia: imaging findings. AJR Am J Roentgenol 163:1105–1110PubMedCrossRef
50.
Hashimoto M, Tate E, Nishii T, et al. (2003) Angiography of hepatic vascular malformations associated with hereditary hemorrhagic telangiectasia. Cardiovasc Intervent Radiol 26:177–180PubMedCrossRef
Metadata
Title
Defining vascular signatures of benign hepatic masses: role of MDCT with 3D rendering
Authors
Sameer Ahmed
Pamela T. Johnson
Elliot K. Fishman
Publication date
01-08-2013
Publisher
Springer US
Published in
Abdominal Radiology / Issue 4/2013
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-012-9956-5

Other articles of this Issue 4/2013

Abdominal Radiology 4/2013 Go to the issue

Letter

Computed tomography features of acinar cell carcinoma of the pancreas

OriginalPaper

Differentiating hepatocellular carcinoma from dysplastic nodules at gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance imaging

OriginalPaper

Oncology imaging in the abdomen and pelvis: where cancer hides

Pictorial Essay

Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up

OriginalPaper

Gadofosveset-enhanced MRI for the assessment of rectal cancer lymph nodes: predictive criteria

OriginalPaper

Pancreatic retention cyst: multi-modality imaging findings and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits